When to Use PQRI and BPOG Language in Filings


When to Use PQRI and BPOG Language in Filings

Published on 08/12/2025

When to Use PQRI and BPOG Language in Filings

Understanding Extractables and Leachables in Pharmaceutical Products

Extractables and leachables (E&L) refer to the chemical compounds that may migrate from packaging materials or container closure systems into pharmaceutical products. The migration can occur through various means such as contact and storage conditions. Understanding these phenomena is critical in ensuring product safety and efficacy. Regulatory bodies, including the FDA in the US and the EMA in the EU, emphasize rigorous testing and assessment of E&L to comply with cGMP regulations.

Pharmaceutical manufacturers must incorporate comprehensive E&L testing into their validation protocols, particularly when working with single-use systems or unique packaging components. Failure to adequately evaluate this can result in significant compliance risks, product recalls, and safety concerns. Regulatory expectations are not just limited to analytical methods but extend to the justification and defensibility of the data generated, including the interpretation of results based on applicable thresholds.

Regulatory Guidelines: PQRI and BPOG

The PQRI (Product Quality Research Institute) and BPOG (Bio-Process Systems Alliance) guidelines offer valuable frameworks for understanding how extractables and leachables should be assessed and reported. Utilizing these guidelines is crucial when preparing regulatory filings, as they provide a pathway to ensuring that submissions are grounded in established scientific principles.

PQRI’s guidelines focus on the analytical evaluation threshold (AET) and the dose-based threshold (DBT), which are critical in assessing risks associated with E&L. The AET is defined as the threshold concentration of extractables at which toxicological evaluation is necessary. Conversely, the DBT provides a means to define acceptable levels of leachables based on the drug’s dosage, intended route of administration, and exposure period.

Both PQRI and BPOG address the need for accurate risk assessments in the drug development process. They emphasize the importance of container closure integrity (CCI) and the potential impact of single-use systems on the E&L profile of a product.

Defining Analytical Evaluation Threshold (AET) and Dose-Based Threshold (DBT)

The establishment of the AET and DBT requires a comprehensive understanding of the risk-benefit profile of a pharmaceutical product. The AET is particularly significant because it ultimately determines whether further toxicological characterization of an extractable is warranted. The criteria commonly utilized to establish the AET hinge on established safety guidelines, such as those published by USP.

Determining the DBT, on the other hand, requires knowledge of the drug’s dosage forms, preparation methods, and intended administration routes. To calculate DBT, a careful analysis of leachables based on their toxicological profiles and potential patient exposure levels must be conducted. Taking into account factors such as single-use systems validation is essential in understanding how manufacturing processes could influence the E&L profile.

Steps for Calculating AET and DBT

  • Step 1: Identify the leachables to be analyzed from packaging components, focusing on the materials used in container closure systems.
  • Step 2: Utilize analytical techniques such as LC-MS/MS or GC-MS to identify and quantify these leachables.
  • Step 3: Compare the concentrations of identified leachables against the AET. If the concentration exceeds AET, further toxicological evaluation is warranted.
  • Step 4: Calculate DBT by determining the acceptable daily exposure of the leachables based on the administered dosage of the drug.
  • Step 5: Finalize the validation study report and ensure alignment with regulatory expectations outlined in applicable guidelines.

Container Closure Integrity (CCI): Importance and Assessment

Container closure integrity (CCI) is a critical quality attribute for ensuring pharmaceutical product safety, particularly when it is susceptible to external influences (e.g., moisture, oxygen). CCI assurance is essential for maintaining sterility, potency, and overall product effectiveness. Regulatory entities such as the ICH have addressed the importance of CCI in their guidelines, emphasizing a risk-based approach to integrity testing.

To validate CCI, appropriate tests should be established, such as seal tests or integrity tests that replicate the conditions of storage and handling. The selection of the test method should be based on the product type, the intended use, and characteristics of the container system. Methods such as pressure decay, vacuum decay, or microbial ingress testing can be employed based on the specific requirements of the product lifecycle.

Implementing CCI Testing in Validation Protocols

  • Step 1: Define the CCI testing criteria as per the regulatory requirements and product specifications.
  • Step 2: Select suitable tests based on product type and risk assessment outcomes; consider if destructive or non-destructive testing is required.
  • Step 3: Execute the CCI testing throughout the product lifecycle, including during stability studies and post-manufacturing evaluations.
  • Step 4: Document findings and integrate the results into the submission package to demonstrate compliance with CCI regulations and guidelines.

Single-Use Systems and Their Impact on E&L Profiles

The adoption of single-use systems in the pharmaceutical industry has revolutionized manufacturing processes. However, the usage of these systems introduces unique E&L challenges. Single-use devices can contain a variety of materials, including plastics and elastomers, which may leach substances into the drug product. As such, they must be rigorously evaluated under PQRI and BPOG guidelines.

When utilizing single-use systems, it is imperative to perform an E&L risk assessment that takes into consideration the specific materials used in manufacturing. Manufacturers are required to evaluate potential extractables in relation to their AET and DBT determinations. This proactive approach supports compliance and minimizes the risk of product contamination.

Steps for Evaluating E&L in Single-Use Systems

  • Step 1: Perform comprehensive material characterization to identify potential extractables.
  • Step 2: Conduct simulated extraction studies to quantify extractables using appropriate solvents and conditions.
  • Step 3: Analyze the extraction data and determine AET and DBT compliance for each identified extractable.
  • Step 4: Document all findings, including risk assessment outcomes, in the final validation report.

Best Practices for Documentation and Filing

Thorough documentation is paramount in the pharmaceutical industry, particularly when submitting filings that involve E&L evaluations and methodologies. Regulatory authorities require transparent and defensible data that support the safety profile of a product.

As part of the documentation process, it is vital to capture the rationale behind the selection of methods, thresholds, and acceptance criteria. Filings should utilize PQRI and BPOG language effectively to demonstrate compliance with established practices and guidelines. Providing comprehensive reports that clearly articulate the risk assessment methodology, E&L data interpretation and impact on product safety is essential in meeting regulatory expectations.

Documentation Checklist for Filings

  • Checklist Item 1: Comprehensive characterization of E&L testing methodologies and rationale.
  • Checklist Item 2: Clear descriptions of the AET and DBT calculations.
  • Checklist Item 3: Verification of CCI test methodologies and results.
  • Checklist Item 4: Summary of E&L risk assessments and any relevant toxicological evaluations.

Conclusion: Navigating E&L Regulations Effectively

Understanding when and how to apply PQRI and BPOG language in regulatory filings is critical for pharmaceutical professionals involved in E&L evaluations. By following the outlined steps and best practices, manufacturers can produce defensible submissions that align with regulatory expectations set forth by authorities such as the FDA and EMA.

Ensuring that E&L evaluations and CCI assessments are thoroughly addressed strengthens product safety and enhances compliance readiness. The industry’s reliance on scientific rigor and systematic risk assessments is paramount to navigating the complexities of extractables and leachables within pharmaceutical product development, commercialization, and lifecycle management.